Browsing by Subject "Male"
Now showing items 21-40 of 331
-
Article
Bone pain in thalassaemia: assessment of DEXA and MRI findings
(1998)An increasing number of adult thalassaemics have been complaining of aches and pains of varying degrees of severity. In a minority the pains are debilitating and there is stiffness in movement. This study is an attempt to ...
-
Article
Brain perfusion SPECT with 99mTC-ECD and serum neuron-specific enolase in patients with spontaneous subarachnoid haemorrhage and clinical vasospasm
(2006)Aim: To estimate the association between single photon emission computed tomography (SPECT) imaging and neuro-specific enolase (NSE) serum level measurement in patients with subarachnoid haemorrhage (SAH) and also to present ...
-
Article
Callous-unemotional traits in incarcerated adolescents
(American Psychological Association Inc, 2014)The presence of callous-unemotional (CU) traits designates a subgroup of antisocial youth at risk for severe, aggressive, and stable conduct problems. As a result, these traits should be considered as part of the criteria ...
-
Article
Can circulated lung cancer cells pass to the urine without apparent urine tract metastases?. A single centre series
(2008)Urine cytology has been a useful tool for the diagnosis of urinary tract malignancies. However, the presence of tumor cells in the urine sediment without an obvious urothelial metastatic deposit is a rare phenomenon and ...
-
Article
Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials
(2010)A growing body of literature suggests that statins may have a chemopreventive potential against melanoma through pleiotropic anti-inflammatory, immunomodulatory, and antiangiogenesis mechanisms. Our aim was to examine this ...
-
Article
Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: A single-center experience and review of the literature
(2014)Background: With the development of modern therapies and better care of patients with autoimmune rheumatic diseases (ARDs) increased survival has been achieved. However, ARDs may share an association with risk of lymphomas ...
-
Article
Cancer of unknown primary (CUP)
(2005)Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...
-
Article
Cancer of unknown primary patients with midline nodal distribution: Midway between poor and favourable prognosis?
(2011)Background: Midline nodal cancer of unknown primary (CUP) has varying definitions and an unclear natural history compared to that of extragonadal germ cell cancer (EGCC) and neuroendocrine tumors. Methods: We systematically ...
-
Article
Cancer of unknown primary site
(2012)Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. ...
-
Article
-
Article
Cancer prevalence and mortality in centenarians: A systematic review
(2012)Life expectancy has dramatically expanded, the global population has aged unprecedentedly and the number of centenarians has significantly increased. The analysis of autopsy series, cancer registries data, vital statistics ...
-
Article
-
Article
[Cantrell's syndrome]
(1987)Congenital diaphragmatic hernia is associated with a high mortality, especially when combined with other defects. The unusual repeated combination of the same congenital abnormalities by a number of patients and the fact ...
-
Article
Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study
(2000)Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...
-
Article
Carcinoma of unknown primary: Natural history and treatment. Analysis of 30 cases and review of the literature
(1990)In this study, the natural history and therapeutic management of 30 patients with carcinoma of unknown primary (CUP syndrome) is presented. Despite detailed laboratory investigations, the primary occult tumor was not ...
-
Article
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG)
(2000)Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...
-
Article
Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features
(2004)Introduction: Patients with cavitating squamous lung carcinoma (cSLC) are believed to harbor aggressive, chemoresistant disease with distinct features and fare poorly. We retrospectively analyzed radiologic, histologic, ...
-
Article
CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: Association with increased 2-year maternal mortality
(2001)The CCR5 chemokine receptor acts as a coreceptor with CD4 to permit infection by primary macrophage-tropic human immunodeficiency virus type 1 (HIV-1) strains. The CCR5Δ32 mutation, which is associated with resistance to ...
-
Article
Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients
(2012)Background: To investigate a possible role of Cefditoren, a recently marketed in Greece third-generation oral cephalosporin in urinary infections of outpatients.Methods: During a multicenter survey of Enterobacteriaceae ...
-
Article
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
(2007)Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...